Domenic A Sica

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi request reprint Pharmacotherapy review: angiotensin-converting enzyme inhibitors
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:485-8. 2005
  2. ncbi request reprint The risks and benefits of therapy with aldosterone receptor antagonist therapy
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    Curr Drug Saf 2:71-7. 2007
  3. ncbi request reprint Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 12:223-6. 2006
  4. ncbi request reprint Importance of potassium in cardiovascular disease
    D A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:198-206. 2002
  5. ncbi request reprint Centrally acting antihypertensive agents: an update
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 9:399-405. 2007
  6. ncbi request reprint The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
    J Clin Hypertens (Greenwich) 4:301-5. 2002
  7. ncbi request reprint Angiotensin receptor blockers and drug-drug interactions
    Domenic A Sica
    Virginia Commonwealth University, Division of Nephrology, Box 980160, MCV Station Medical College of Virginia, Richmond, Virginia 23298 0160, USA
    Expert Opin Drug Saf 4:139-40. 2005
  8. ncbi request reprint Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298, USA
    Am J Cardiol 98:1L-4L. 2006
  9. ncbi request reprint Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice
    D A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 3:383-7. 2001
  10. ncbi request reprint Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats
    Domenic A Sica
    Medical College of Virginia, Virginia Commonwealth University, Box 980160 MCV Station, Richmond, VA 23298 0160, USA
    Drugs 62:443-62. 2002

Detail Information

Publications81

  1. ncbi request reprint Pharmacotherapy review: angiotensin-converting enzyme inhibitors
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:485-8. 2005
    ..This article is the first in a series describing important pharmacotherapeutic considerations of the individual drug classes used in the treatment of hypertension...
  2. ncbi request reprint The risks and benefits of therapy with aldosterone receptor antagonist therapy
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    Curr Drug Saf 2:71-7. 2007
    ..As such, steps should be taken to lessen the likelihood of its occurring if therapy is being contemplated with agents in this class...
  3. ncbi request reprint Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 12:223-6. 2006
    ..These new pulmonary observations in patients afflicted with an ACE inhibitor-related cough should revive interest in this bothersome side effect...
  4. ncbi request reprint Importance of potassium in cardiovascular disease
    D A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:198-206. 2002
    ..Because of the complexity of this topic, issues of hyperkalemia will be addressed in a forthcoming manuscript...
  5. ncbi request reprint Centrally acting antihypertensive agents: an update
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 9:399-405. 2007
    ..Escalating doses of drugs in this class often give rise to salt and water retention, in which case diuretic therapy becomes a valuable adjunctive therapy...
  6. ncbi request reprint The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
    J Clin Hypertens (Greenwich) 4:301-5. 2002
    ..The results of this trial are both interesting and relevant to what is an expanding use of angiotensin-receptor blockers in the hypertensive population...
  7. ncbi request reprint Angiotensin receptor blockers and drug-drug interactions
    Domenic A Sica
    Virginia Commonwealth University, Division of Nephrology, Box 980160, MCV Station Medical College of Virginia, Richmond, Virginia 23298 0160, USA
    Expert Opin Drug Saf 4:139-40. 2005
    ..Moreover, this drug class is devoid of relevant class-specific side effects. These features provide some of the basis for the excellent tolerance of drugs in this class...
  8. ncbi request reprint Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298, USA
    Am J Cardiol 98:1L-4L. 2006
  9. ncbi request reprint Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice
    D A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 3:383-7. 2001
    ..Additional clarifying studies are needed to determine if specific patient subsets exist that might benefit from such combination therapy...
  10. ncbi request reprint Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats
    Domenic A Sica
    Medical College of Virginia, Virginia Commonwealth University, Box 980160 MCV Station, Richmond, VA 23298 0160, USA
    Drugs 62:443-62. 2002
    ..If made truly cost-competitive, it will gain an increasing share of the hypertensive market. If not, market forces will relegate it to a secondary role for hypertension treatment...
  11. ncbi request reprint Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:21-6. 2005
    ..Despite the potential for side effects with CCBs, their potent blood pressure-lowering effect makes them a prerequisite for blood pressure control in many patients...
  12. ncbi request reprint Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations
    Domenic A Sica
    Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Congest Heart Fail 11:163-6. 2005
    ..The specific risk:benefit ratio for individual cardiovascular medications should be more routinely considered in the context of gender...
  13. ncbi request reprint Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis
    Domenic A Sica
    Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
    Heart Fail Rev 10:23-9. 2005
    ..This is more apt to occur with spironolactone due to the very long half-life of several of its active metabolites...
  14. ncbi request reprint Novel combinations in the treatment of hypertension
    D A Sica
    Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA, USA
    Minerva Urol Nefrol 57:129-39. 2005
    ..Such novel pharmacologic approaches offer useful options for treatment in the otherwise difficult to control hypertensive patient...
  15. ncbi request reprint Clinical pharmacokinetics of losartan
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, PO Box 980160, Richmond, VA 23298, USA
    Clin Pharmacokinet 44:797-814. 2005
    ..Losartan, like other angiotensin-receptor antagonists, is devoid of significant adverse effects...
  16. ncbi request reprint Calcium channel blockers and the kidney
    Domenic Sica
    Section of Clinical Pharamcology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA
    Clin Cornerstone 6:39-52. 2004
    ..Non-DHP CCBs could potentially attenuate sympathetic activity and reduce protein excretion in patients with CKD...
  17. ncbi request reprint Optimizing hypertension and vascular health: focus on ethnicity
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA
    Clin Cornerstone 6:28-38. 2004
    ..Calcium channel blockers are distinctive for their potent blood pressure-lowering effects, and novel strategies such as chronotherapeutic dosing of these agents has further improved upon the flexibility of their use...
  18. ncbi request reprint New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Box 980160, MCV Station, Richmond VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 7:188-93. 2005
    ..The neutral findings in this trial add a new wrinkle to the concept of class effect for cardiovascular protection with angiotensin-converting enzyme inhibitors in patients with coronary artery disease...
  19. ncbi request reprint Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Box 980160, MCV Station, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 7:59-64. 2005
  20. ncbi request reprint Current concepts of pharmacotherapy in hypertension: thiazide-type diuretics: ongoing considerations on mechanism of action
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:661-4. 2004
    ..Understanding these issues is important to the effective use of these compounds...
  21. ncbi request reprint Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 10:259-64. 2004
    ..The frequency of such scrutiny should be patient-specific and based on the constellation of risk factors for hyperkalemia...
  22. ncbi request reprint Hypertension, renal disease, and drug considerations
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:24-30. 2004
    ..A number of questions still remain unanswered in the pharmacotherapy of chronic kidney disease, including the optimal dose for these drugs as well as what represents the most favorable achieved blood pressure...
  23. ncbi request reprint Diuretic-related side effects: development and treatment
    Doemnic A Sica
    Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, MCV Station Box 980160, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:532-40. 2004
    ..This article reviews the commonly encountered side effects with the various diuretic classes. Where indicated, the mechanistic basis and treatment of such side effects is further discussed...
  24. ncbi request reprint The risks and benefits of aldosterone antagonists
    Domenic A Sica
    Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
    Curr Heart Fail Rep 2:65-71. 2005
    ..Hyperkalemia should be considered as a possibility in any patient receiving these medications and as such is best addressed preemptively...
  25. ncbi request reprint Angiotensin-converting enzyme inhibitor use in the year 2005
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 7:8-11. 2005
    ..The future of this drug class remains bright. Other drug classes, such as angiotensin receptor blockers, have narrowed-but not entirely closed-the outcomes gap that exists between these two drug classes...
  26. ncbi request reprint Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 9:78-86. 2007
    ..Additional outcomes trials, which are currently proceeding to their conclusion, may provide the necessary proof to support an expanded use of these 2 drug classes in combination...
  27. ncbi request reprint Baroreflex activation for the treatment of hypertension: principles and practice
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Division of Nephrology, Box 980160, MCV Station, Richmond, VA 23298 0160, USA
    Expert Rev Med Devices 3:595-601. 2006
    ..Clinical trials designed to evaluate the efficacy and safety of this therapy in patients with resistant hypertension are now underway in both Europe and the USA...
  28. ncbi request reprint Transdermal clonidine: therapeutic considerations
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:558-62. 2005
    ..The not infrequent development of a dermatitis, together with a substantially greater cost than oral clonidine, have been the major undoings for transdermal clonidine...
  29. ncbi request reprint Interaction of grapefruit juice and calcium channel blockers
    Domenic A Sica
    Department of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, USA
    Am J Hypertens 19:768-73. 2006
    ..The calcium channel blocker and grapefruit juice interaction should be incorporated into the knowledge base of rational therapeutics for the prescribing physician...
  30. ncbi request reprint Angiotensin receptor blockers: new considerations in their mechanism of action
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 8:381-5. 2006
    ..As the mechanistic basis for the action(s) of angiotensin receptor blockers more completely unfolds, added credence may ultimately be lent to widely touted and often overstated intraclass differences...
  31. ncbi request reprint Hyponatremia and heart failure--treatment considerations
    Domenic A Sica
    Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 12:55-60. 2006
    ..Vasopressin receptor antagonists will redefine the treatment of heart failure-related hyponatremia and may possibly evolve as adjunct therapies to loop diuretics in diuretic-resistant patients...
  32. ncbi request reprint Antihypertensive therapy and its effects on potassium homeostasis
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 8:67-73. 2006
    ..Guidelines for the monitoring of serum potassium levels in the setting of antihypertensive therapy are at best makeshift and often drawn from the know-how of the treating physician...
  33. ncbi request reprint Pharmacotherapy review: calcium channel blockers
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 8:53-6. 2006
    ..Despite the sometimes discomforting side effects seen with calcium channel blocker therapy, their robust blood pressure-lowering effect makes them an important component of most multidrug regimens used for blood pressure control...
  34. ncbi request reprint Alpha1-adrenergic blockers: current usage considerations
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:757-62. 2005
    ....
  35. ncbi request reprint Pharmacotherapy review: Angiotensin receptor antagonists
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 7:681-4. 2005
    ..Results from a series of outcomes trials increasingly support the use of drugs in this class as cardioprotective and renoprotective agents in patients with heart failure, diabetic nephropathy, and post-myocardial infarction...
  36. ncbi request reprint Hyponatremia and heart failure--pathophysiology and implications
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298, USA
    Congest Heart Fail 11:274-7. 2005
    ..The recent availability of vasopressin receptor antagonists, however, offers a different approach to the management of this complex electrolyte disturbance, but one that is still evolving as to the scope of its clinical benefits...
  37. ncbi request reprint Calcium channel blockers: monotherapy and dual therapy considerations in the treatment of hypertension
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
    Am J Cardiovasc Drugs 7:1-3. 2007
    ..provides data from INVEST (INternational VErapamil-Trandolapril STudy), which shows the particular utility of a CCB and ACE inhibitor combination in bringing elderly hypertensive patients with CAD to goal BP when monotherapy..
  38. ncbi request reprint Pathologic basis and treatment considerations in chronic kidney disease-related hypertension
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    Semin Nephrol 25:246-51. 2005
    ....
  39. ncbi request reprint Calcium channel blockers: a more expansive treatment role
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 7:2-4. 2005
  40. ncbi request reprint What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure?
    D A Sica
    Department of Medicine and Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Blood Press Monit 4:S9-S16. 1999
    ..Additional studies of an integrative nature will be necessary to obtain more complete definition of the dynamic interplay between nutrition and various neurohumoral axes in determining how nocturnal blood pressure patterns are expressed...
  41. ncbi request reprint The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, 23298 0160, USA
    J Renin Angiotensin Aldosterone Syst 3:247-54. 2002
    ..These attributes would favour the increased use of ARBs in this population...
  42. ncbi request reprint Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 8:334-41, 345. 2002
    ..The need to reduce renin-angiotensin aldosterone system activity in a heart failure patient would seem to justify the small risk of angioedema with ARB therapy in a patient having previously experienced ACE inhibitor-related angioedema...
  43. ncbi request reprint Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?
    D A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
    J Clin Hypertens (Greenwich) 4:441-5. 2002
    ..Time and additional clinical experience with eplerenone will establish its safety profile and determine if the original label for this compound was correct...
  44. ncbi request reprint Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?
    Domenic A Sica
    Department of Medicine, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:375-80. 2002
    ..Such justification might include the presence of heart failure or proteinuric nephropathic states among other considerations...
  45. ncbi request reprint Doxazosin and congestive heart failure
    Domenic A Sica
    Department of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Congest Heart Fail 8:178-84. 2002
    ..A valued member of our therapeutic armamentarium need not be laid entirely to rest; rather, doxazosin should now be viewed as a secondary or tertiary antihypertensive therapy pending a more complete review of the ALLHAT data...
  46. ncbi request reprint Premature termination of clinical trials--lessons learned
    D A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:219-25. 2002
    ..Early termination of a clinical trial can have important clinical implications and, in particular, can redirect patterns of clinical practice...
  47. ncbi request reprint ACE inhibitors and stroke: new considerations
    Domenic A Sica
    Department of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:126-9, 133. 2002
  48. ncbi request reprint 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, USA
    Curr Opin Nephrol Hypertens 11:123-33. 2002
    ..Polypharmacy and altered drug metabolism increase the risk of myotoxicity, albeit to an ill-defined degree, in this population. Many factors should enter into the choice of a statin in the multiply medicated renal failure patient...
  49. ncbi request reprint Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 1060, USA
    J Clin Hypertens (Greenwich) 4:52-7. 2002
    ..An evidence-based therapeutic approach derived from these trials would argue for ARBs to be the foundation of therapy in the patient with type 2 diabetes and nephropathy...
  50. ncbi request reprint Rhabdomyolysis and statin therapy: relevance to the elderly
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Am J Geriatr Cardiol 11:48-55. 2002
    ..Physicians must take many factors into account when selecting a member of the HMG-CoA reductase inhibitor class, particularly as relates to their use in the multiply medicated elderly patient...
  51. ncbi request reprint The importance of the sympathetic nervous system and systolic hypertension in patients with hypertension: benefits in treating patients with increased cardiovascular risk
    D A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    Blood Press Monit 5:S19-25. 2000
    ..This may provide an explanation for the differential effect on systolic blood pressure exhibited by this compound...
  52. ncbi request reprint Disposition and safety of omapatrilat in subjects with renal impairment
    D A Sica
    Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
    Clin Pharmacol Ther 68:261-9. 2000
    ..Omapatrilat, a vasopeptidase inhibitor, preserves natriuretic peptides and inhibits the renin angiotensin aldosterone system by simultaneously inhibiting neutral endopeptidase and angiotensin-converting enzyme...
  53. ncbi request reprint Class effects of angiotensin-converting enzyme inhibitors
    D A Sica
    Department of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298 0160, USA
    Am J Manag Care 6:S85-108; quiz S109-11. 2000
    ..In addition, for some agents clinical trials that demonstrate decreased morbidity or mortality are currently lacking...
  54. ncbi request reprint Pharmacokinetics and blood pressure response of losartan in end-stage renal disease
    D A Sica
    Division of Clinical Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298 0160, USA
    Clin Pharmacokinet 38:519-26. 2000
    ..Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension. This compound is in common use in populations with renal failure and end-stage renal disease (ESRD)...
  55. ncbi request reprint Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease
    D A Sica
    Division of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298 0160, USA
    Drug Saf 22:350-60. 2000
    ....
  56. ncbi request reprint Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia Commonwealth University, Richmond 23298, USA
    Curr Opin Nephrol Hypertens 12:123-31. 2003
    ..To characterize the pharmacokinetics and pharmacodynamics of the different calcium-channel blockers...
  57. ncbi request reprint Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Medical College of Virginia of Virginia Commonwealth University, MCBV Station Box 980160, Richmond, VA 23298 0160, USA
    Congest Heart Fail 9:224-9. 2003
    ....
  58. ncbi request reprint The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 6:231-41. 2004
    ..Propranolol CR is an effective antihypertensive formulation that may reduce blood pressure during the morning period of maximum cardiovascular risk...
  59. ncbi request reprint Hypertension and end-organ disease in African Americans: case presentations
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, 1101 East Marshall Street, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:48-53. 2004
  60. ncbi request reprint EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:91-5. 2004
    ....
  61. ncbi request reprint Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 5:414-20. 2003
    ..Additional clarifying studies are required to establish whether specific patient subsets exist that might benefit from such combination therapy...
  62. ncbi request reprint ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials
    Domenic A Sica
    Virginia Commonwealth University, MCV Station Box 980160, Richmond, VA 23298 0160, USA
    Congest Heart Fail 10:160-4. 2004
    ....
  63. ncbi request reprint Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 9:287-92. 2003
    ..However, the exact role of torsemide in the outpatient management of congestive heart failure remains to be determined...
  64. ncbi request reprint Calcium channel blocker-related periperal edema: can it be resolved?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 5:291-4, 297. 2003
    ..Discontinuing the CCB and switching to an alternative antihypertensive therapy will resolve the edema...
  65. ncbi request reprint Minoxidil: an underused vasodilator for resistant or severe hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 6:283-7. 2004
    ..There is, however, a place for minoxidil in the treatment of resistant hypertension especially in patients with advanced renal disease...
  66. ncbi request reprint Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations
    Domenic A Sica
    Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertensiion, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:410-6. 2004
    ..This review discusses the physiologic and non-physiologic basis for side effects with ACE inhibition...
  67. ncbi request reprint Are current strategies for treating hypertension effective?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 5:23-32. 2003
    ....
  68. ncbi request reprint Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Heart Dis 5:176-81. 2003
    ..Bioavailability was similar for both formulations of propranolol. Propranolol CR exhibited appropriate pharmacokinetics for a chronotherapeutic approach to the treatment of hypertension...
  69. ncbi request reprint Metolazone and its role in edema management
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Congest Heart Fail 9:100-5. 2003
    ..The temptation should be avoided to simply reduce the doses of either metolazone or the loop diuretic as a means to controlling an active diuresis...
  70. ncbi request reprint The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 5:159-67. 2003
    ..It remains to be determined if this represents a class effect for all angiotensin-converting enzyme inhibitors...
  71. ncbi request reprint Aldosterone-receptor antagonism and end-stage renal disease
    Niall McLaughlin
    Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Box 980160, Richmond, VA 23298, USA
    Curr Hypertens Rep 6:327-30. 2004
    ..Eplerenone has not been studied in ESRD in a therapeutic or safety capacity. Additional studies are needed with these compounds in the ESRD population before their use can be considered safe...
  72. ncbi request reprint Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans
    Jackson T Wright
    Department of Medicine, Division of Hypertension, Case Western Reserve University, Cleveland, Ohio, USA
    Am J Hypertens 17:734-42. 2004
    ....
  73. ncbi request reprint Use of enoxaparin in patients with chronic kidney disease: safety considerations
    Donald F Brophy
    Department of Pharmacy, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, Virginia 23298 0533, USA
    Drug Saf 30:991-4. 2007
  74. doi request reprint Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system
    Siddhartha S Ghosh
    Division of Nephrology, VCU Medical Center, Virginia Commonwealth University, MCV Station, Box 980160, Richmond, VA, 23298 0160, USA
    Pediatr Nephrol 24:367-77. 2009
    ..Furthermore, AKT (activated via alpha1A receptors), as well as increased alpha1A receptors and their agonist NE, might contribute to the observed hypertrophy...
  75. ncbi request reprint Sodium and water retention in heart failure and diuretic therapy: basic mechanisms
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    Cleve Clin J Med 73:S2-7; discussion S30-3. 2006
    ....
  76. ncbi request reprint The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    J Renin Angiotensin Aldosterone Syst 3:66-71. 2002
    ..Additional clarifying studies are needed to establish whether specific patient subsets exist that might benefit from such combination therapy...
  77. pmc Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss
    Harvey J Sugerman
    Division of General Trauma Surgery, Department of Surgery, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0519, USA
    Ann Surg 237:751-6; discussion 757-8. 2003
    ..To evaluate the preoperative relationships of hypertension and diabetes mellitus in severe obesity and the effects of gastric bypass (GBP)-induced weight loss...
  78. ncbi request reprint Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
    Janice G Douglas
    Case Western Reserve University, Department of Medicine, Room W 165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
    Arch Intern Med 163:525-41. 2003
  79. ncbi request reprint Angiotensin-converting enzyme inhibitor-related angioedema: recognition and treatment
    Maureen P Flattery
    Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Prog Cardiovasc Nurs 22:47-51. 2007
  80. ncbi request reprint Acute phosphate nephropathy following colonoscopy preparation
    Daniel E Carl
    Department of Medicine, Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    Am J Med Sci 334:151-4. 2007
  81. ncbi request reprint Rationale for combination therapy in the treatment of hypertension
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    J Renin Angiotensin Aldosterone Syst 3:63-5. 2002
    ..Like most matters in the clinical sector the approach to a disease in this case hypertension should remain highly individualised and cognisant of what can be significant cost considerations...